Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial

Graeme J Hankey, Werner Hacke, J Donald Easton, S Claiborne Johnston, Jean-Louis Mas, Danielle M Brennan, Deepak L Bhatt, Keith A A Fox, Eric J Topol, CHARISMA Trial Investigators

Research output: Contribution to journalArticlepeer-review

Abstract

Disabling stroke is costly and considered by some patients a fate worse than death. We aimed to determine whether clopidogrel reduces the rate and functional severity of stroke among high vascular risk patients, including patients with previous transient ischemic attack or ischemic stroke, who were enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial.
Original languageEnglish
Pages (from-to)1679-83
Number of pages5
JournalStroke
Volume41
Issue number8
DOIs
Publication statusPublished - Aug 2010

Fingerprint Dive into the research topics of 'Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial'. Together they form a unique fingerprint.

Cite this